Lonza to purchase biologics website from Roche in U.S. for $1.2 billion By Reuters


© Reuters. The emblem of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. REUTERS/Arnd Wiegmann/file picture

ZURICH (Reuters) -Swiss contract drug producer Lonza mentioned on Wednesday it has signed an settlement to accumulate the Genentech manufacturing facility in Vacaville, California, from drugmaker Roche for $1.2 billion in money.

Lonza plans to take a position round 500 million Swiss francs ($562.30 million) to improve the power and improve capabilities on the website to accommodate the subsequent era of mammalian biologics therapies, the corporate mentioned in an announcement.

“The Vacaville website is a extremely priceless strategic acquisition that can make capability instantly obtainable for our prospects and unlock future progress for our Biologics division,” Jean-Christophe Hyvert, president of Biologics at Lonza, mentioned within the assertion.

The transaction is anticipated to shut within the second half of 2024, topic to customary closing situations.

Basel-based Lonza additionally mentioned it had up to date its 2024-2028 steerage to a gross sales progress vary of 12-15% compound annual progress charge in contrast with a 11-13% estimate beforehand.

The Vacaville facility presently has a complete bioreactor capability of round 330,000 liters, making it one of many largest biologics manufacturing websites worldwide by quantity, Lonza mentioned.


Source link

Related Articles

Back to top button